U.S. stock index futures are showing a mixed performance this Friday morning, September 19, 2025, as investors digest a recent Federal Reserve interest rate cut and look ahead to upcoming economic data. After major indexes closed at record highs on Thursday, premarket trading suggests a cautious start to the day, with S&P 500 (SPX), Nasdaq 100 (US100:IND), and Dow Jones Industrial Average (INDU) futures experiencing slight fluctuations. This follows a period of robust gains driven by optimism surrounding mo ...

REDWOOD CITY, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical-stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, announced today the pricing of its underwritten public offering of (i) an aggregate of 11,670,707 shares of its common stock and accompanying commo ...

How many speculative stocks can you own this year. We've seen fortunes made in speculative stocks. And by speculative, I mean companies that don't turn a profit or maybe they have some earnings, but you're paying a ridiculous mold for them.I've wrestled mightily with this particular question from my chapel trust. I spoke a bit about it in today's investing club meeting. The answer might surprise you.I am actually all in favor of speculation, but it's got to be done wisely. In fact, if you're younger, I actu ...

Key Points A crucial meeting with a regulator didn't seem to go well. It was about a leading pipeline drug being developed by the company. 10 stocks we like better than Replimune Group › On Thursday, Replimune (NASDAQ: REPL) had a crucial meeting with federal regulators regarding one of its leading drug candidates. While the outcome of the event wasn't necessarily negative, it left the future of the drug up in the air, and investors didn't like that uncertainty. As a result, they assertively traded ...

In trading on Thursday, shares of Dyne Therapeutics Inc (Symbol: DYN) crossed above their 200 day moving average of $13.82, changing hands as high as $13.98 per share. Dyne Therapeutics Inc shares are currently trading up about 5.9% on the day. The chart below shows the one year performance of DYN shares, versus its 200 day moving average:Looking at the chart above, DYN's low point in its 52 week range is $6.36 per share, with $37.08 as the 52 week high point — that compares with a last trade of $13.92. C ...

REDWOOD CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical-stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, announced today that it intends to offer and sell in an underwritten public offering, subject to market and other conditions, shares of its common ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma, and healthcare industries and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?I have given Novavax, Inc. (NASDAQ: NVAX ) stock three straight Sell recommendations in my last three articles on the Gaithersburg, Maryland-based vaccine maker, in October 2024 , February this year , and mostThe g ...

Healthcare payment concept with stethoscope and big money US dollar.gettyMost Wall Street “suits” are allergic to dividend cuts. These spreadsheet jockeys sooooo lack imagination. They prefer linear trends—up and to the right.Dividend growers model nicely. Payout “resets” (cuts!) do not. So, there is often a knee-jerk reaction from analysts to sell every divvie slash they see.Same goes for most individual income investors. These vanilla beans sold BlackRock Health Sciences Term Trust (BMEZ) late last week w ...

投资服务内容 - 提供生物技术、制药和医疗保健行业股票的动态跟踪和关键趋势解读 [1] - 为新手和经验丰富的生物技术投资者提供催化剂关注点及买入卖出评级 [1] - 涵盖所有大型制药公司的产品销售和预测、综合财务报表、贴现现金流分析和市场分析 [1] 分析师背景 - 分析师为生物技术顾问 覆盖生物技术、医疗保健和制药行业超过5年 [1] - 分析师已汇编超过1000家公司的详细报告 [1] - 分析师领导投资团体Haggerston BioHealth [1]

Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros statement on media inquiry concerning former Board member Schlieren (Zurich), Switzerland, September 18, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, has become aware of a possible imminent publication in a Dutch financial media outlet regarding the recent resignation of Albert Arp, a former member of the company’s Board of Directors. Kuros has received inquiries from the m ...